In a significant development for India’s pharmaceutical sector, global pharma major Lupin Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility.

The EIR follows a product-specific Pre-Approval Inspection conducted by the U.S. FDA between September 1 and September 5, 2025, signaling that the facility meets the agency’s stringent global quality and compliance benchmarks.

Confirming the development, Nilesh Gupta, Managing Director of Lupin, said, “We are pleased to have received the EIR from the U.S. FDA for our Aurangabad facility. This underscores our commitment to upholding the highest standards of quality and compliance, and delivering trusted healthcare solutions to patients worldwide.”

The clearance further strengthens Lupin’s reputation as one of India’s leading pharmaceutical exporters to the U.S. market, which remains the world’s largest and most tightly regulated healthcare landscape. Industry experts view the EIR as a positive milestone that reinforces confidence in India’s pharmaceutical manufacturing capabilities and regulatory adherence.

The company’s Aurangabad unit plays a crucial role in Lupin’s global supply chain, producing key formulations for multiple therapeutic segments. With this latest nod from the U.S. FDA, Lupin is expected to move ahead with new product approvals and market expansions in the United States.

The development comes at a time when Indian pharmaceutical companies are increasingly focusing on strengthening compliance frameworks to align with evolving global standards, ensuring the country’s continued leadership in supplying affordable, high-quality medicines worldwide.